



## **Phlecs Full Body Blue Light receives the innovation award at the International Ageing Fit Conference**

High Tech Campus Eindhoven, the Netherlands

March 14, 2022

Out of 25 European competing projects, Phlecs has received the innovation award at the Ageing Fit Conference on the 2<sup>nd</sup> of March 2022 for its Full Body Blue Light device (more information at <https://www.ageingfit-event.com/2022-innovation-pitches/>).

Itching is highly prevalent among the older adults. Studies in the Netherlands and in Denmark show that up to 50% of nursing home residents suffer from Chronic Itching. Furthermore, comorbidities such as 'hypertension' -affecting more than 70% of the people aged 65 years plus- and 'depression' that raises up to 50% in the nursing home population.

Current treatments have important limitations, because of overmedication, potential side effects and the time it requires to provide skin care, when care givers capacity is scarce. Because of that, adherence to treatments is low and this significantly impacts the quality of life of our parents and grandparents.

Phlecs is only 3 years old but leverages more than 15 years of clinical research and technology development originated at Philips. In particular, studies show that blue light, that is UV-free so easy and safe to administrate, is effective to reduce itching, hypertension and depression. These clinical results are confirmed with the most recent studies conducted at the Universities of Lodz in Poland and Düsseldorf in Germany using the Full Body Blue Light device developed by Phlecs.

David Aubert, Phlecs CEO and Co-founder comments: *"Phlecs is delighted to receive the Ageing Fit 2022 innovation award, for their Full Body Blue Light device that leverages more than 15 years of clinical research and technology. Elderly itching impacts significantly older adults' quality of life and current treatments have important limitations due to overmedication, potential side effects and the time it requires to provide skin care. Ageing Fit 2022 was the perfect place for Phlecs to introduce its innovation, the Full Body Blue Light, a phototherapy device that treats elderly itching, and related comorbidities such as hypertension and depression. Ageing Fit 2022 has been very successful for us, we have made many contacts with potential customers and partners. We are grateful to receive this award because it will help us to increase the market traction and convince investors for the Series A round, we have just initiated."*



From left to right: David Aubert (CEO) and Rene Wenmekers (Chief Quality & Regulatory)

## About AgeingFit

AgeingFit is the first European event fostering innovation for well-being in older age, gathering all actors involved in the innovation cycle from research to market, along with the key players implicated in regulation and evaluation with the objective to identify tomorrow's market needs and promote today's innovative products and services for healthy ageing.

## About Phlecs

Phlecs is a Dutch start-up founded by 4 former PHILIPS employees with many years of experience in photo-dermatology. Over the last 15 years extensive clinical research has been conducted on photo-dermatology treatments using UV-free LED lighting. Many studies (<https://www.phlecs.com/clinical-studies/>) have been published that show the efficacy of blue light therapy for the treatment of skin diseases such as Psoriasis, Eczema or itching. New studies, not yet published, confirm the safety and effectiveness of blue light therapy for the treatment of inflammatory skin diseases such as elderly itching. The Phlecs Full Body Blue Research device that has been introduced last year after obtaining the medical CE certification. The device is currently used by dermatology clinics to do research on blue light and will be used in large nursing homes that have the facility to provide the treatment. Phlecs has initiated the development of a Full Body Home connected device that brings therapy at patient's bed with 2 patent filings this year. This device will be launched in 2026, sold to care homes and home care service providers.

For more information: [www.phlecs.com](http://www.phlecs.com)  
[david.aubert@phlecs.com](mailto:david.aubert@phlecs.com)